SEC Form 4 · accession 0000914190-15-000293
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Charles R. Kummeth
Officer — Chief Executive Officer · Director
Period of report
Aug 7, 2015
Accepted (ET)
Aug 11, 2015 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 7, 2015 | A | 11,522 | $0.00 | A | 44,377 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $108.49 | Aug 7, 2015 | A | 79,517 | A | — | Aug 7, 2022 | Common Stock | 79,517 | 79,517 | D |
| Stock Option (Right to Buy)F9 | $108.49 | Aug 7, 2015 | A | 79,517 | A | — | Aug 7, 2022 | Common Stock | 79,517 | 79,517 | D |
| Restricted Stock UnitF8,F9 | — | Aug 7, 2015 | A | 11,522 | A | — | — | Common Stock | 11,522 | 11,522 | D |
| Stock Option (Right to Buy)F2 | $67.46 | holding | — | — | — | — | Apr 1, 2020 | Common Stock | 65,000 | 65,000 | D |
| Stock Option (Right to Buy)F3 | $67.46 | holding | — | — | — | — | Apr 1, 2020 | Common Stock | 50,000 | 50,000 | D |
| Stock Option (Right to Buy)F4 | $86.25 | holding | — | — | — | — | Apr 1, 2021 | Common Stock | 46,316 | 46,316 | D |
| Stock Option (Right to Buy)F5 | $94.35 | holding | — | — | — | — | Aug 12, 2021 | Common Stock | 80,460 | 80,460 | D |
| Restricted Stock UnitF8,F6 | — | holding | — | — | — | — | — | Common Stock | 11,129 | 11,129 | D |
Explanation of responses
- F1Includes (i) 5,000 shares of restricted stock that vest on April 1, 2016, (ii) 5,102 shares for which the risk of forfeiture will lapse with respect to 2,551 shares on April 1, 2016 and April 1, 2017; (iii) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; and (iv) 11,522 shares for which the risks of forfeiture will lapse with respect to 3,840 shares on August 7, 2016 and 3,841 shares on each of August 7, 2017 and August 7, 2018.
- F2The option will vest pursuant to the following schedule: 8,125 shares on October 1, 2013, 1,354 shares on the first day of each month for the period beginning November 1, 2013 and ending March 1, 2017, and 1,361 shares on April 1, 2017.
- F3Fully exercisable pursuant to achievement of performance goals.
- F4The option will vest pursuant to the following schedule: 5,790 shares on October 1, 2014, 965 shares on the first day of the month for the period beginning November 1, 2014 and ending March 1, 2018, and 961 shares on April 1, 2018.
- F5Vests in full or in part if certain performance goals are achieved during each of the 2015, 2016 and 2017 fiscal years.
- F6Vests in full or in part if certain performance goals are achieved during each of the 2015, 2016 and 2017 fiscal years (previously reported in Table I).
- F719,879 shares vest on each of August 7, 2016, August 7, 2017 and August 7, 2018 and 19,880 shares vest on August 7, 2019.
- F8Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F9Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.